The facility operates from Investigational New Drug through to commercial supply. The project was recognized for addressing one of the most persistent bottlenecks in antibody-drug conjugate (ADC) manufacturing: a highly fragmented supply chain. BSP has consolidated drug substance (DS) conjugation and sterile drug product (DP) fill-finish in one facility, with one quality system, eliminating multi-site handoffs that have historically complicated the clinical and commercial scale supply chain.
Learn More